Immutep ADRs Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has issued a reminder to investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency in clinical trials that could impact future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which underscores its expertise and effectiveness in handling similar cases, thereby enhancing investor confidence.
- Investor Guidance: The firm advises investors to select counsel with proven success to avoid partnering with intermediaries lacking actual litigation capabilities, ensuring they receive the best legal support and potential compensation in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.480
Low
12.00
Averages
12.00
High
12.00
Current: 0.480
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep ADRs Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm has issued a reminder to investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency in clinical trials that could impact future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which underscores its expertise and effectiveness in handling similar cases, thereby enhancing investor confidence.
- Investor Guidance: The firm advises investors to select counsel with proven success to avoid partnering with intermediaries lacking actual litigation capabilities, ensuring they receive the best legal support and potential compensation in the class action.
See More
Immutep Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, concerning securities transactions from March 24, 2025, to March 12, 2026, with a deadline for participation set for July 6, 2026.
- False Statements Allegation: The complaint alleges that Immutep concealed the true results of its TACTI-004 trial of eftilagimod alfa, as the company claimed “strong operational progress” in a Form-K filed with the SEC on January 30, 2026, despite knowing the trial would fail to meet its primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep's misleading statements came to light, indicating that the company's public disclosures throughout the class period were false, which severely impacted investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for affected investors, encouraging them to take action before class certification to ensure their rights are protected.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep Limited, alleging violations of federal securities laws between March 24, 2025, and March 12, 2026, indicating significant investor dissatisfaction with the company's transparency.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of its TACTI-004 trial, claiming that statements about “strong operational progress” lacked a reasonable basis, potentially undermining investor confidence in the company's future.
- Increased Risk Warning: Executives at Immutep are accused of knowing, based on internal clinical data, that the risk of the TACTI-004 trial failing to meet primary efficacy and/or safety endpoints had materially increased, yet they failed to disclose this critical information to investors, which could lead to significant losses.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, with the law firm offering services on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Immutep Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Immutep on behalf of investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, indicating potential misleading statements that could affect investor rights.
- Allegation Details: The lawsuit claims that Immutep concealed critical data regarding the TACTI-004 clinical trial, asserting strong progress while significant risks existed, leading to investor losses once the truth was revealed.
- Investor Action Deadline: Affected investors must apply by July 6, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency and importance of legal proceedings for protecting their interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in investor protection matters.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, allowing potential lead plaintiffs to apply by July 6, 2026, indicating the legal process is underway.
- Compensation Potential: Investors joining the class action may be entitled to compensation without any upfront costs, which reduces the financial burden on investors and encourages more affected parties to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Immutep made false or misleading statements during the TACTI-004 trial, concealing the true status of the trial, which led to investor losses when the actual information was disclosed, highlighting the company's lack of transparency in clinical trials.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Lawsuit Announced for Immutep Ltd. ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Receipts (ADRs) of Immutep Ltd. (NASDAQ: IMMP) from March 24, 2025, to March 12, 2026, indicating potential misleading statements by the company during this period that led to investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek financial redress, thereby enhancing investor confidence in the process.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, indicating a lack of transparency in clinical trials that could impact the company's future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases, which may attract more investors to join the lawsuit.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm has issued a reminder to investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency in clinical trials that could impact future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which underscores its expertise and effectiveness in handling similar cases, thereby enhancing investor confidence.
- Investor Guidance: The firm advises investors to select counsel with proven success to avoid partnering with intermediaries lacking actual litigation capabilities, ensuring they receive the best legal support and potential compensation in the class action.
See More
Immutep Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, concerning securities transactions from March 24, 2025, to March 12, 2026, with a deadline for participation set for July 6, 2026.
- False Statements Allegation: The complaint alleges that Immutep concealed the true results of its TACTI-004 trial of eftilagimod alfa, as the company claimed “strong operational progress” in a Form-K filed with the SEC on January 30, 2026, despite knowing the trial would fail to meet its primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep's misleading statements came to light, indicating that the company's public disclosures throughout the class period were false, which severely impacted investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for affected investors, encouraging them to take action before class certification to ensure their rights are protected.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep Limited, alleging violations of federal securities laws between March 24, 2025, and March 12, 2026, indicating significant investor dissatisfaction with the company's transparency.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of its TACTI-004 trial, claiming that statements about “strong operational progress” lacked a reasonable basis, potentially undermining investor confidence in the company's future.
- Increased Risk Warning: Executives at Immutep are accused of knowing, based on internal clinical data, that the risk of the TACTI-004 trial failing to meet primary efficacy and/or safety endpoints had materially increased, yet they failed to disclose this critical information to investors, which could lead to significant losses.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, with the law firm offering services on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Immutep Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Immutep on behalf of investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, indicating potential misleading statements that could affect investor rights.
- Allegation Details: The lawsuit claims that Immutep concealed critical data regarding the TACTI-004 clinical trial, asserting strong progress while significant risks existed, leading to investor losses once the truth was revealed.
- Investor Action Deadline: Affected investors must apply by July 6, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency and importance of legal proceedings for protecting their interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in investor protection matters.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, allowing potential lead plaintiffs to apply by July 6, 2026, indicating the legal process is underway.
- Compensation Potential: Investors joining the class action may be entitled to compensation without any upfront costs, which reduces the financial burden on investors and encourages more affected parties to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Immutep made false or misleading statements during the TACTI-004 trial, concealing the true status of the trial, which led to investor losses when the actual information was disclosed, highlighting the company's lack of transparency in clinical trials.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Lawsuit Announced for Immutep Ltd. ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Receipts (ADRs) of Immutep Ltd. (NASDAQ: IMMP) from March 24, 2025, to March 12, 2026, indicating potential misleading statements by the company during this period that led to investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek financial redress, thereby enhancing investor confidence in the process.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, indicating a lack of transparency in clinical trials that could impact the company's future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases, which may attract more investors to join the lawsuit.
See More
